SCHEDULE: BlackRock Discloses 9.0% Stake in Emergent BioSolutions

BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 9.0% in Emergent BioSolutions Inc. as of June 30, 2026.

Summary

• BlackRock, Inc. has updated its Schedule 13G filing, indicating a beneficial ownership of 4,651,339 shares of Emergent BioSolutions Inc. common stock.
• This represents 9.0% of the class of securities outstanding.
• The filing is an amendment, specifically Amendment No. 1, to a previous Schedule 13G.
• The reporting entity is BlackRock, Inc., organized in Delaware.
• The principal executive offices of Emergent BioSolutions Inc. are located at 300 Professional Dr, Gaithersburg, MD 20879.
• BlackRock's principal business office is at 50 Hudson Yards, New York, NY 10001.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It is a routine disclosure of beneficial ownership by a major institutional investor and does not contain operational or financial performance updates from the company itself.

Positives

• BlackRock's continued investment suggests confidence in Emergent BioSolutions' long-term prospects.
• A significant institutional investor like BlackRock holding a substantial stake can provide market stability.

Negatives

• The filing is an amendment, which could imply a change in BlackRock's position or a correction of previous filings, though the details are not provided.
• The specific reasons for the increase or change in stake are not detailed in this filing.

Risks

• The filing does not explicitly detail new risks, but any significant institutional ownership change can be perceived as a market signal.
• Potential for future changes in BlackRock's stake, which could impact share price.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from Emergent BioSolutions Inc. It is a disclosure of beneficial ownership by BlackRock, Inc.

Management Comments

• "In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the "Reporting Business Units") of BlackRock, Inc. and its subsidiaries and affiliates. It does not include securities, if any, beneficially owned by other business units whose beneficial ownership of securities are disaggregated from that of the Reporting Business Units in accordance with such release."
• "Various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the common stock of EMERGENT BIOSOLUTIONS INC. No one person's interest in the common stock of EMERGENT BIOSOLUTIONS INC is more than five percent of the total outstanding common shares."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that significant shifts in institutional ownership, as indicated by this Schedule 13G filing from BlackRock, can signal evolving investor sentiment and potential strategic interests within the biotechnology and pharmaceutical sectors, particularly for companies like Emergent BioSolutions that operate in specialized areas.

Stakeholder Impact

• Shareholders: May view BlackRock's significant stake as a positive indicator of institutional support, potentially influencing share price.
• Management: May consider BlackRock's position in strategic discussions, though the filing states no intent to influence control.
• Analysts: Will use this information to update ownership models and assess institutional interest in Emergent BioSolutions.

Next Steps

• Monitor future filings from BlackRock, Inc. for any further changes in beneficial ownership.
• Observe Emergent BioSolutions Inc.'s operational and financial performance for insights into the rationale behind BlackRock's investment.

Key Dates

Keywords

Emergent BioSolutions, BlackRock, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Amendment